Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of brca-Related Ovarian Cancer Patients?

International Journal of Gynecological Cancer

Volumn 19, Issue 9, 2009, Pages 1501-1504

  Leunen, Karin ^a   Cadron, Isabelle ^a   Van Gorp, Toon ^a   Amant, Frédéric ^a   Berteloot, Patrick ^a   Neven, Patrick ^a   Legius, Eric ^b   Vergote, Ignace ^a  

^a Department of Obstetrics and Gynecology   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

BRCA; Dose dense regimen; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; CARBOPLATIN; PACLITAXEL;

AGED; ARTICLE; CARCINOMA; CELL TRANSFORMATION; DOSE RESPONSE; EVALUATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; OVARY TUMOR; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARBOPLATIN; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85026143071     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181bb703f     Document Type: Article

References (0)